JP7482031B2 - 新規の抗ｐｄ－１抗体 - Google Patents

新規の抗ｐｄ－１抗体 Download PDF

Info

Publication number
JP7482031B2
JP7482031B2 JP2020550711A JP2020550711A JP7482031B2 JP 7482031 B2 JP7482031 B2 JP 7482031B2 JP 2020550711 A JP2020550711 A JP 2020550711A JP 2020550711 A JP2020550711 A JP 2020550711A JP 7482031 B2 JP7482031 B2 JP 7482031B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020550711A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019179396A5 (https=
JP2021518137A (ja
JP2021518137A5 (https=
Inventor
ユンイン チェン，
ジン リ，
Original Assignee
ウーシー バイオロジクス アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウーシー バイオロジクス アイルランド リミテッド filed Critical ウーシー バイオロジクス アイルランド リミテッド
Publication of JP2021518137A publication Critical patent/JP2021518137A/ja
Publication of JPWO2019179396A5 publication Critical patent/JPWO2019179396A5/ja
Publication of JP2021518137A5 publication Critical patent/JP2021518137A5/ja
Priority to JP2024007290A priority Critical patent/JP2024029261A/ja
Application granted granted Critical
Publication of JP7482031B2 publication Critical patent/JP7482031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020550711A 2018-03-20 2019-03-18 新規の抗ｐｄ－１抗体 Active JP7482031B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024007290A JP2024029261A (ja) 2018-03-20 2024-01-22 新規の抗ｐｄ－１抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810255570.3 2018-03-20
CN201810255570 2018-03-20
CN2018079631 2018-03-20
CNPCT/CN2018/079631 2018-03-20
PCT/CN2019/078515 WO2019179396A1 (en) 2018-03-20 2019-03-18 Novel anti-pd-1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024007290A Division JP2024029261A (ja) 2018-03-20 2024-01-22 新規の抗ｐｄ－１抗体

Publications (4)

Publication Number Publication Date
JP2021518137A JP2021518137A (ja) 2021-08-02
JPWO2019179396A5 JPWO2019179396A5 (https=) 2022-03-16
JP2021518137A5 JP2021518137A5 (https=) 2022-03-16
JP7482031B2 true JP7482031B2 (ja) 2024-05-13

Family

ID=67986701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550711A Active JP7482031B2 (ja) 2018-03-20 2019-03-18 新規の抗ｐｄ－１抗体
JP2024007290A Pending JP2024029261A (ja) 2018-03-20 2024-01-22 新規の抗ｐｄ－１抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024007290A Pending JP2024029261A (ja) 2018-03-20 2024-01-22 新規の抗ｐｄ－１抗体

Country Status (7)

Country Link
US (2) US12030941B2 (https=)
EP (1) EP3768724A4 (https=)
JP (2) JP7482031B2 (https=)
CN (2) CN116333126A (https=)
CA (1) CA3093992A1 (https=)
TW (1) TWI829677B (https=)
WO (1) WO2019179396A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024029261A (ja) * 2018-03-20 2024-03-05 ウーシー バイオロジクス アイルランド リミテッド 新規の抗ｐｄ－１抗体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112442122B (zh) * 2019-09-04 2021-09-21 上海洛启生物医药技术有限公司 阻断型pd-1纳米抗体及其编码序列和用途
CN114430746B (zh) * 2019-09-25 2023-09-01 上海药明生物技术有限公司 新型抗pd-l1抗体
WO2021063201A1 (zh) * 2019-09-30 2021-04-08 四川科伦博泰生物医药股份有限公司 抗pd-1抗体及其用途
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
CN118240082A (zh) * 2020-12-28 2024-06-25 浙江纳米抗体技术中心有限公司 Pd-1结合分子及其应用
US20240092908A1 (en) * 2020-12-31 2024-03-21 Zhejiang Doer Biologics Co., Ltd. Anti-pd-1 single-domain antibody
WO2022161454A1 (zh) * 2021-01-29 2022-08-04 明慧医药（杭州）有限公司 抗原结合蛋白及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2009114335A2 (en) * 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
CN106432494B9 (zh) 2015-08-11 2022-02-15 广州誉衡生物科技有限公司 新型抗-pd-1抗体
MA43260A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
CN106046162B (zh) * 2016-06-21 2019-04-02 大庆东竺明生物技术有限公司 抗人程序性死亡因子1（pd-1）单克隆抗体的制备及应用
CN107474135B (zh) * 2017-02-17 2020-08-18 广西医科大学 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
CN116333126A (zh) * 2018-03-20 2023-06-27 上海药明生物技术有限公司 新型抗pd-1抗体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024029261A (ja) * 2018-03-20 2024-03-05 ウーシー バイオロジクス アイルランド リミテッド 新規の抗ｐｄ－１抗体

Also Published As

Publication number Publication date
EP3768724A4 (en) 2022-04-13
CN112236454B (zh) 2022-09-13
TWI829677B (zh) 2024-01-21
JP2021518137A (ja) 2021-08-02
TW202003563A (zh) 2020-01-16
CA3093992A1 (en) 2019-09-26
CN112236454A (zh) 2021-01-15
US12030941B2 (en) 2024-07-09
EP3768724A1 (en) 2021-01-27
WO2019179396A1 (en) 2019-09-26
US20210061912A1 (en) 2021-03-04
CN116333126A (zh) 2023-06-27
US20240301067A1 (en) 2024-09-12
JP2024029261A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
JP7482031B2 (ja) 新規の抗ｐｄ－１抗体
CN110204614B (zh) 抗人lag-3单克隆抗体及其制备方法和用途
US12371493B2 (en) Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof
CN111978402B (zh) 新型cldn18.2结合分子
US12570746B2 (en) Anti-PD-L1 antibodies
CN111978403B (zh) 新型cldn18.2结合分子
CN112552411B (zh) 新型抗pd-l1/抗lag-3双特异性抗体及其用途
WO2023222017A1 (en) Anti-b7h3 antibody and uses thereof
WO2024146553A1 (en) Antibodies against cd47, method for preparing the same, and use thereof
WO2024251140A1 (en) Anti-tigit antibodies and uses thereof
HK40044140A (en) Novel anti-pd-1 antibodies
HK40044140B (en) Novel anti-pd-1 antibodies
HK40032484A (en) Novel cldn18.2 binding molecule
HK40033235A (en) Novel cldn18.2 binding molecule

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240426

R150 Certificate of patent or registration of utility model

Ref document number: 7482031

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150